VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 800 shares, a decrease of 96.4% from the November 30th total of 22,500 shares. Based on an average daily trading volume, of 7,800 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Truvestments Capital LLC acquired a new position in VanEck Biotech ETF in the third quarter valued at about $44,000. FSA Wealth Management LLC acquired a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at approximately $54,000. Coastline Trust Co bought a new stake in VanEck Biotech ETF during the 3rd quarter worth approximately $59,000. Wilmington Savings Fund Society FSB acquired a new stake in VanEck Biotech ETF during the 3rd quarter worth approximately $166,000. Finally, Tyler Stone Wealth Management lifted its stake in VanEck Biotech ETF by 79.5% in the third quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after buying an additional 652 shares in the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Down 0.6 %

NASDAQ BBH traded down $0.95 during trading on Friday, reaching $158.24. 9,084 shares of the company traded hands, compared to its average volume of 7,332. The stock’s 50 day moving average price is $166.22 and its two-hundred day moving average price is $172.47. VanEck Biotech ETF has a 1-year low of $151.35 and a 1-year high of $183.64.

VanEck Biotech ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.